ClinicalTrials.gg
CompletedNCT07550699Updated Sep 8, 2026

Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton

An interventional study of ABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES) in Acquired Brain Injury (Including Stroke), Spinal Cord Injury and Multiple Sclerosis, sponsored by ABLE Human Motion S.L.. Completed at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary objective of this study is to validate the safety and clinical performance of the ABLE Exoskeleton with integrated Functional Electrical Stimulation (ABLE FES) in individuals with neurological conditions that impair gait, including spinal cord injury, acquired brain injury, and multiple sclerosis.

The secondary objective is to collect preliminary data on the potential clinical and psychosocial benefits of combining robotic gait assistance with electrical stimulation.

Read the detailed description

This is a pre-post, single-centre, quasi-experimental study with an estimated duration of 16 weeks. The study will be conducted at therapy2people GmbH (Vienna, Austria). A minimum of 15 participants (5 per subgroup: spinal cord injury, acquired brain injury, multiple sclerosis) will be recruited within a period of up to 8 weeks.

After providing informed consent, participants will undergo a screening visit to confirm eligibility based on predefined inclusion and exclusion criteria. At the latest, one week after screening, participants will complete a baseline assessment.

The intervention will consist of 8 gait training sessions with the ABLE Exoskeleton with Functional Electrical Stimulation integration(ABLE FES), performed twice per week over 4-5 weeks. Each session will last approximately 60 minutes and include donning/doffing, walking training, and safety/performance assessments. Electrode placement and stimulation parameters will be adapted to the participant's neurological condition.

Outcome measures will focus on device safety (adverse events, serious adverse events, withdrawals) and clinical performance (donning/doffing time, walking distance, number of steps, standing time, therapist assistance, gait parameters, and motor torque). Additional measures will include lower limb spasticity, pain, perceived exertion, user satisfaction, and tolerance to FES.

For safety monitoring during sessions involving functional electrical stimulation (FES) with the exoskeleton, vital signs including heart rate and blood pressure will be measured before, during, and after the intervention sessions.

At the latest, one week after the last training session, a post-training assessment will be conducted. Two weeks later, participants will return for a follow-up visit to record any adverse events since the end of training.

This study will provide valuable evidence on the safety, feasibility, and potential rehabilitation benefits of integrating functional electrical stimulation into a robotic exoskeleton for patients with neurological gait impairments.

02

Conditions studied

  • Acquired Brain Injury (Including Stroke)
  • Spinal Cord Injury
  • Multiple Sclerosis

Keywords

  • Gait training
  • Wearable exoskeleton
  • Acquired Brain Injury
  • Lower-limb exoskeleton
  • Spinal Cord Injury
  • Multiple Sclerosis
  • Functional Electrical Stimulation (FES)
  • Robotic exoskeleton
  • Hybrid exoskeleton-FES system
03

In context

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

This study's enrollment of 14 is below the median of 41 across 613 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

ABLE Human Motion S.L. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years old
  • Diagnosis of acquired brain injury, spinal cord injury (neurological level between C5 and L2, AIS B to AIS D), or multiple sclerosis
  • Currently undergoing physiotherapy treatment, either as an inpatient or outpatient at the investigating center
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Significant osteoporosis that may increase the risk of fracture
  • Unresolved fractures in the pelvis or limbs, or a history of fragility fractures in the lower limbs within the past 2 years
  • Spinal instability (or use of spinal orthoses, unless medically approved)
  • Deterioration >3 points of the total in the motor score of the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) in the last 4 weeks. Loss of sensation and/or motor activity above the level of injury detected that has not been evaluated by a doctor.
  • Severe spasticity: Level 4 on the Modified Ashworth Scale
  • Orthostatic hypotension: Inability to tolerate at least 10 minutes in an upright position
  • Uncontrolled autonomic dysreflexia
  • Medical instability
  • Unstable cardiovascular condition, hemodynamic instability, untreated hypertension (SBP > 140 mmHg, DBP > 90 mmHg), deep vein thrombosis (DVT), or uncontrolled autonomic dysreflexia
  • Severe comorbidities, including any condition deemed inappropriate by the investigator for using the ABLE Exoskeleton or for completing the study
  • Pressure ulcers Grade I or higher (as defined by the European Pressure Ulcer Advisory Panel - EPUAP) in areas that will be in contact with the device
  • Anthropometric measurements incompatible with the ABLE Exoskeleton, specifically height outside the 1.5-1.9 m range or weight exceeding 100 kg
  • Anatomical constraints (such as leg length differences, users unable to position themselves inside the device) that are incompatible with the device
  • Range of motion restrictions preventing normal gait or sit-to-stand transitions, including: Ankle: ability to achieve at least neutral (0°) position; Knee: ability to extend to at least -10°; Hip: bilateral hip flexion of at least 100° and extension of at least 0°
  • Heterotopic ossification
  • Pregnant or breastfeeding women
  • Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures
  • Requires assisted ventilation.
  • Scoliosis >40-50º Cobb angle.
  • Presence of pacemakers, defibrillators, or other non-compatible electronic implants.
  • Open wounds, infections, or active irritation at the electrode placement sites.
  • Severe dermatological conditions in the stimulation area.
  • Uncontrolled active epilepsy.
  • Malignant tumors in the area of application.
  • Severe loss of sensation in the areas where electrodes are to be placed.
  • Medical conditions where electrical stimulation is by physician recommendation.
  • Inability to communicate pain, discomfort, or adverse reactions during stimulation.
  • Venous thrombosis, thrombophlebitis, or severe arterial obstruction.
  • Chronic venous insufficiency with significant varicosities.
  • Hemophilia.
  • Ongoing infectious process or fever.
  • Presence of metallic implants in the flow area between the electrodes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Gait training with ABLE Exoskeleton + Functional Electrical Stimulation (ABLE FES)

    Participants will undergo 8 rehabilitation sessions over 4-5 weeks using the ABLE Exoskeleton with Functional Electrical Stimulation integration (ABLE FES). Each session will last approximately 60 minutes and include donning/doffing, gait training, and functional assessments. Electrode placement and stimulation parameters will be adapted to the participant's pathology (spinal cord injury, acquired brain injury, or multiple sclerosis). Participants will also complete baseline, post-training, and follow-up assessments.

    Device: ABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)

Interventions

  • DeviceABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)

    A robotic lower-limb exoskeleton integrated with functional electrical stimulation (ABLE FES) used for gait rehabilitation training.

06

What researchers measure

Primary outcomes

  1. Number and type of device-related Adverse Events

    To assess safety, the number of Severe Adverse Events (SAE), Adverse Events (AE), and withdrawals related to the device will be recorded and classified by type and severity throughout the study period.

    Time frame: From baseline to follow-up (up to 2 weeks after end of intervention)

  2. Time taken to don/doff the device

    The time taken to don and doff the ABLE Exoskeleton with FES will be measured during each gait training session. Donning time will start from the moment the participant is ready to transfer into the device until all straps and clips are tightened. Doffing time will start from the moment the participant begins removing the device until it is fully removed. Time will be reported in minutes and seconds.

    Time frame: Up to 5 weeks (8 sessions)

  3. Number of steps walked

    In each gait training session, the number of steps taken with the device (step count) will be automatically measured and recorded by the device.

    Time frame: Up to 5 weeks (8 sessions)

  4. Distance walked

    In each gait training session, the distance walked with the device will be automatically measured and recorded by the device and reported in meters.

    Time frame: Up to 5 weeks (8 sessions)

  5. Time spent upright and time spent walking

    In each gait training session, the time spent upright and the time spent walking with the device will be automatically measured and recorded by the device and reported in minutes.

    Time frame: Up to 5 weeks (8 sessions)

  6. Number of therapists assisting the session

    In each gait training session, the number of therapists assisting the participant during the session will be recorded.

    Time frame: Up to 5 weeks (8 sessions)

  7. Assistive device used

    In each gait training session, the assistive device used (walker, crutches, cane, second therapist, etc) will be recorded.

    Time frame: Up to 5 weeks (8 sessions)

  8. Step Length

    Step length (in cm) will be automatically measured and recorded during each gait training session by the device.

    Time frame: Up to 5 weeks (8 sessions)

  9. Step Symmetry

    Step symmetry (in %) will be automatically measured and recorded during each gait training session by the device.

    Time frame: Up to 5 weeks (8 sessions)

  10. Center of mass displacement (cm)

    In each gait training session, the center of mass displacement (cm) will be automatically measured and registered by the device

    Time frame: Up to 5 weeks (8 sessions)

  11. Motor torque (Nm)

    In each gait training session, the motor torque (Nm) will be automatically measured and registered by the device

    Time frame: Up to 5 weeks (8 sessions)

Secondary outcomes

  1. FES tolerance

    Tolerance to Functional Electrical Stimulation (FES) will be assessed using a custom single-item ordinal scale developed by the research team during each training session. Scores range from 0 to 4, where 0 = no perception (no sensation felt), 1-3 represent increasing levels of perceived stimulation, and 4 = painful (uncomfortable or painful stimulus). This scale is descriptive; higher scores indicate greater perceived stimulation intensity, with the highest score reflecting an uncomfortable or painful stimulus.

    Time frame: During each training session (up to 5 weeks, 8 sessions)

  2. Clinical observation

    Clinical observations will be assessed using a structured questionnaire developed by the research team, consisting of 4 yes/no items completed during each session.

    Time frame: During each training session (up to 5 weeks, 8 sessions)

  3. Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score

    The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience

    Time frame: Post-training (up to 6 weeks)

  4. Borg Rating of Perceived Exertion

    The Borg Rating of Perceived Exertion (RPE) scale (0-10) will be used to evaluate perceived physical effort before and after each training session. Scores range from 0 (no exertion) to 10 (maximal exertion), with higher scores indicating greater perceived effort.

    Time frame: From baseline to post-training (up to 6 weeks)

  5. Location and level of pain

    The location and level of pain using the numeric rating scale (NRS) will be assessed. Each value is scored on a 0 to 10 scale, where 0 represents no pain and 10 represents the worst pain imaginable.

    Time frame: From baseline to post-training (up to 6 weeks)

  6. Lower limb spasticity

    The Modified Ashworth Scale (MAS) will be used to measure lower limb spasticity. Scores range from 0 (no increase in muscle tone) to 4 (rigid).

    Time frame: At baseline and post-training (up to 6 weeks)

  7. Minimum tolerated assistance in Functional Test

    Exoskeleton assistance level (%) tolerated by the patient for at least 5 minutes, when progressively reducing assistance levels during a 30-minute walk with the exoskeleton and without FES.

    Time frame: At baseline, each training session (4-5 weeks) and post-training (up to 6 weeks)

07

Study locations

1 site
  • therapy2people GmbH
    Vienna, State of Vienna 1220, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Sep 2026, 4 months.

Of 298 interventional studies with no phase under Brain Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 24, 2026
StartActual
Apr 20, 2026
Primary completionActual
Sep 3, 2026
CompletionActual
Sep 3, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07550699
Lead sponsor
ABLE Human Motion S.L.
Collaborators
therapy2people GmbH
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Apr 20, 2026
Primary completion
Sep 3, 2026
Completion
Sep 3, 2026
Last update
Sep 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion